Elson P J, Kvols L K, Vogl S E, Glover D J, Hahn R G, Trump D L, Carbone P P, Earle J D, Davis T E
Dana-Farber Cancer Institute, Boston, MA.
Invest New Drugs. 1988 Jun;6(2):97-103. doi: 10.1007/BF00195367.
One hundred and forty-four evaluable patients with recurrent or metastatic renal cell carcinoma (RCC) were treated with vinblastine infusion (n = 35), L-alanosine (n = 36), acivicin (n = 27), or aminothiadiazole (n = 46). Observed objective response rates of 9%, 3%, 4%, and 2%, respectively indicate that noe of these agents has significant antineoplastic activity in recurrent or metastatic RCC. Multivariate analysis of survival data suggests that initial performance status, time from initial diagnosis to study entry, and the presence or absence of lung metastases are important prognostic factors for survival. After adjustment for these factors, treatment assignment was also seen to be of prognostic value. All four treatments were generally well tolerated. There were no reports of life-threatening or lethal toxicities; however, 37% of the patients experienced severe reactions to treatment, primarily myelosuppression, anemia, neuropathies, and mucositis.
144例可评估的复发性或转移性肾细胞癌（RCC）患者接受了长春碱输注治疗（n = 35）、L - 丙氨酸（n = 36）、阿西维辛（n = 27）或氨基噻二唑（n = 46）治疗。观察到的客观缓解率分别为9%、3%、4%和2%，这表明这些药物在复发性或转移性RCC中均无显著的抗肿瘤活性。生存数据的多因素分析表明，初始体能状态、从初始诊断到进入研究的时间以及是否存在肺转移是生存的重要预后因素。在对这些因素进行调整后，治疗分配也被认为具有预后价值。所有四种治疗的耐受性总体良好。没有危及生命或致命毒性的报告；然而，37%的患者出现了严重的治疗反应，主要是骨髓抑制、贫血、神经病变和粘膜炎。
